Former Komen grantee Dr. Aditya Bardia explains how metastatic estrogen receptor-positive breast cancers can develop mutations in the estrogen receptor gene, or ESR1. These mutations typically arise after treatment with aromatase inhibitors, which eliminate estrogen from the body. The breast cancer develops ESR1 mutations so that it is no longer dependent on estrogen for growth. Komen Scholar Dr. Donald McDonnell explains how these mutations are different from inherited gene mutations like mutations in the BRCA1 and BRCA2 genes. Dr. Bardia also explains how ESR1 mutations are detected.
Kelsey Hampton, PhD, is Senior Manager, Mission Communications at Susan G. Komen
Dr. Aditya Bardia is a medical oncologist at Massachusetts General Hospital
Dr. Donald McDonnell is a research scientist at Duke University
Sign up for reminders about future episodes of Breast Cancer Breakthroughs here: [ Ссылка ]
Link to Survey: [ Ссылка ]
Clinical Trial Finder: [ Ссылка ]
Videos:
Breast Cancer Breakthroughs Episode 7: Brining Treatments to Life: [ Ссылка ]
Under the Microscope: Mutations: [ Ссылка ]
Under the Microscope: Estrogen Receptor: [ Ссылка ]
Resources:
Metastatic Breast Cancer: [ Ссылка ]
Hormone Receptor Status: [ Ссылка ]
Hormone therapy for metastatic breast cancer: [ Ссылка ]
Monitoring metastatic breast cancer: [ Ссылка ]
Emerging areas in diagnosis: [ Ссылка ]
Emerging areas in metastatic breast cancer treatment: [ Ссылка ]
EMERALD Trial (Active, not recruiting): [ Ссылка ]
